A Randomized Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Single Dose Administration in Subjects With Systemic Lupus Erythematosus
Latest Information Update: 18 May 2015
At a glance
- Drugs Blisibimod (Primary) ; Blisibimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 18 May 2015 New trial record